Relmada Therapeutics (RLMD) Total Non-Current Liabilities (2014 - 2018)

Relmada Therapeutics (RLMD) has reported Total Non-Current Liabilities for 5 consecutive years, with $4.4 million the latest figure, recorded in Q2 2018.

• In Q2 2018, Total Non-Current Liabilities rose 263.64% year-over-year to $4.4 million; the TTM figure through Jun 2018 stood at $4.4 million (up 263.64% YoY), while the FY2018 annual figure was $4.4 million, up 263.64% from the prior year.
• Total Non-Current Liabilities improved to $4.4 million in Q2 2018 per RLMD's latest filing, from $1.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $28.1 million in Q4 2014 and bottomed at $1.2 million in Q2 2017.
• Historically, Total Non-Current Liabilities has averaged $6.5 million across 5 years, with a median of $2.2 million in 2016.
• Annual changes were most pronounced in 2016 — Total Non-Current Liabilities plunged 90.48% — and 2018, when it surged 263.64%.
• Relmada Therapeutics' Total Non-Current Liabilities stood at $28.1 million in 2014, then sank by 94.37% to $1.6 million in 2015, then slipped by 10.63% to $1.4 million in 2016, then retreated by 15.03% to $1.2 million in 2017, then soared by 263.64% to $4.4 million in 2018.
• Business Quant data shows RLMD's Total Non-Current Liabilities at $4.4 million in Q2 2018, $1.2 million in Q2 2017, and $1.2 million in Q1 2017.